Literature DB >> 8441279

Ewing's sarcoma.

R S Iyer1, S R Rao, A Gurjal, C N Nair, S K Pai, P A Kurkure, S C Pande, S H Advani.   

Abstract

Between 1984-1987, 50 patients with Ewing's sarcoma of the bone were entered on combined modality protocol at Tata Memorial Hospital. Protocol treatment involved induction therapy consisting of 6-week therapy with vincristine, Adriamycin (doxorubicin), and cyclophosphamide (VDC) followed by local radiotherapy 50 Gy to the involved bone. This was followed for six more cycles of VDC. Five patients had metastatic disease at presentation. Seventy-six percent (38/50) of patients had disease either at axial or proximal site. With a median follow-up of 48 months (range 14-87) 21 patients remained alive with disease-free survival of 38.0% +/- 2.5% at 5 years and overall survival of 36.0% +/- 2.6% at 5 years. Twenty-five patients relapsed with five patients developing local failure and four local and distant metastasis. Using Lee-Desu statistical methods, only response to therapy was a significant factor for survival. We conclude that more aggressive therapy with proper selection of local treatment modality including surgery and/or radiotherapy is required to produce more long-term survival in high-risk Ewing's sarcoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8441279     DOI: 10.1002/jso.2930520315

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Outcome of multimodality treatment of Ewing's sarcoma of the extremities.

Authors:  Akshay Tiwari; Himesh Gupta; Sandeep Jain; Gauri Kapoor
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

2.  Short-term followup after surgical treatment of Ewing's sarcoma.

Authors:  Shishir Rastogi; Ashok Kumar; Himanshu Gupta; Shah Alam Khan; Sameer Bakhshi
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

3.  Chemotherapy in Ewing's sarcoma.

Authors:  Sandeep Jain; Gauri Kapoor
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.